Letter ·
NAMD Warns Against Broadly Defining Pharmaceutical Value-Based Purchasing in Draft PAVE Act
NAMD wrote to Congress expressing concern with draft legislation that would broadly define pharmaceutical value-based purchasing in a manner that could undermine the Medicaid drug rebate program.
In 2019, Senators Cassidy and Warner introduced the Patient Affordability Value and Efficiency Act, which sought to broadly define pharmaceutical value-based purchasing. In this letter, NAMD warns that such a broad definition would negatively impact fundamental aspects of the Medicaid drug rebate program and increase Medicaid pharmacy benefit spending.
Related resources
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program's inflationary rebates.
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.